ARVN
Arvinas, Inc.
NasdaqGSUSDEQUITY
Healthcare
DELAYED
Sell
-43/100
Last price
7.29
▼ 0.17 (2.29%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
7.77
Prev close
7.46
Day high
7.49
Day low
7.28
Volume
585.79K
Market cap
$471.65M
P/E (TTM)
28.12
52W range
6.97 – 14.51
Day trading desk
Gap from prior close
+4.16%
Prior close 7.46
VWAP
7.33
-0.60% from price
Relative volume
1.25×
Normal
Session range
16.39%
7.20 – 8.38
Position in range
8%
Near session low
ATR (14D)
0.33
4.48% of price
Prior day high
7.51
PDH
Prior day low
7.22
PDL
Bid / ask spread
—
Quote not published
Session volume
981.77K
Avg 783.05K
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-2.53%
-4.5%
1M
-22.15%
-23.3%
3M
-14.60%
-19.1%
6M
-35.71%
-53.9%
YTD
-38.36%
-52.6%
1Y
-23.93%
-40.4%
3Y
-62.78%
-145.0%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on ARVN open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
+39.20K
Net buying
Buy transactions
6
93.16K shares
Sell transactions
8
53.96K shares
Net transactions
+14
Buys less sells
Sell : buy shares
0.6 : 1
Mixed
Insider-held shares
5.10M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Jun 24, 26 | NORWALK LESLIE V Director |
STOCK | 15.53K | $0 | Direct |
| Jun 24, 26 | CUNNINGHAM EVERETT V Director |
STOCK | 15.53K | $0 | Direct |
| Jun 24, 26 | BAIN LINDA C Director |
STOCK | 15.53K | $0 | Direct |
| Jun 24, 26 | SMALDONE ALSUP LAURIE Director |
STOCK | 15.53K | $0 | Direct |
| Jun 24, 26 | MORRISON BRIGGS W. M.D. Director |
STOCK | 15.53K | $0 | Direct |
| Jun 24, 26 | SAIK ANDREW Chief Financial Officer |
SELL | 5.70K | $46.47K | Direct |
| Jun 24, 26 | KENNEDY EDWARD MOORE JR. Director |
STOCK | 15.53K | $0 | Direct |
| Jun 17, 26 | CACACE ANGELA M Officer |
SELL | 2.58K | $19.57K | Direct |
| May 21, 26 | TEEL RANDY Chief Executive Officer |
SELL | 2.21K | $19.96K | Direct |
| May 11, 26 | BERKOWITZ NOAH Officer |
SELL | 11.11K | $110.39K | Direct |
| May 11, 26 | SAIK ANDREW Chief Financial Officer |
SELL | 11.14K | $110.69K | Direct |
| May 11, 26 | LOOMIS DAVID K Officer |
SELL | 1.92K | $19.07K | Direct |
| May 11, 26 | TEEL RANDY Chief Executive Officer |
SELL | 9.66K | $95.97K | Direct |
| May 11, 26 | CACACE ANGELA M Officer |
SELL | 9.66K | $95.97K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
BERKOWITZ NOAH |
Officer | 191.40K | Sale |
CACACE ANGELA M |
Officer | 180.39K | Sale |
CUNNINGHAM EVERETT V |
Director | 41.57K | Stock Award(Grant) |
HOUSTON JOHN G |
Director | 1.12M | Sale |
KENNEDY EDWARD MOORE JR. |
Director | 84.29K | Stock Award(Grant) |
MORRISON BRIGGS W. M.D. |
Director | 111.55K | Stock Award(Grant) |
NORWALK LESLIE V |
Director | 41.57K | Stock Award(Grant) |
SAIK ANDREW |
Chief Financial Officer | 187.43K | Sale |
TAYLOR IAN |
Officer | 159.12K | Sale |
TEEL RANDY |
Chief Executive Officer | 285.01K | Sale |
Fundamentals
Market cap$471.65M
Enterprise value$-81.93M
Revenue (TTM)$316.70M
Gross profit$307.70M
EBITDA$-9.90M
Net income$9.30M
EPS (TTM)$0.26
Free cash flow$-94.50M
Total cash$567.90M
Total debt$8.00M
Book value / share$8.61
Shares outstanding64.52M
Float56.81M
Short % of float8.89%
Dividend yield0.00%
Beta (5Y)1.81
Valuation & profitability ratios
Trailing P/E28.12
Forward P/E-2.26
PEG ratio—
Price / sales—
Price / book0.85
EV / revenue-0.26
EV / EBITDA8.28
Gross margin97.16%
Operating margin66.36%
Profit margin2.94%
Return on equity1.59%
Return on assets-1.01%
Debt / equity1.42
Current ratio7.91
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $262.60M | $263.40M | $78.50M | $131.40M | -0.3% |
| Operating revenue | $262.60M | $263.40M | $78.50M | $131.40M | -0.3% |
| Research & development | $285.20M | $348.20M | $379.70M | $315.00M | -18.1% |
| Selling, general & admin | $95.90M | $165.40M | $100.30M | $79.60M | -42.0% |
| Total operating expense | $381.10M | $513.60M | $480.00M | $394.60M | -25.8% |
| Operating income | -$118.50M | -$250.20M | -$401.50M | -$263.20M | +52.6% |
| Net interest income | $38.40M | $54.80M | $38.80M | $12.00M | -29.9% |
| Pre-tax income | -$80.50M | -$198.30M | -$363.90M | -$251.00M | +59.4% |
| Tax provision | $300.00K | $600.00K | $900.00K | $20.90M | -50.0% |
| Net income | -$80.80M | -$198.90M | -$367.30M | -$282.50M | +59.4% |
| Net income to common | -$80.80M | -$198.90M | -$367.30M | -$282.50M | +59.4% |
| Basic EPS | -1.14 | -2.77 | -6.62 | -5.31 | +58.8% |
| Diluted EPS | -1.14 | -2.77 | -6.62 | -5.31 | +58.8% |
| EBIT | -$118.50M | -$250.20M | -$401.50M | -$263.20M | +52.6% |
| EBITDA | -$113.30M | -$243.60M | -$394.80M | -$255.00M | +53.5% |
| Basic shares | 70.90M | 71.90M | 55.50M | 53.20M | -1.4% |
| Diluted shares | 70.90M | 71.90M | 55.50M | 53.20M | -1.4% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $142.90M | $100.50M | $311.70M | $81.30M | +42.2% |
| Cash & short-term investments | $685.40M | $1.04B | $1.26B | $1.21B | -34.1% |
| Accounts receivable | $1.00M | $5.70M | $0 | $1.00M | -82.5% |
| Total current assets | $700.70M | $1.07B | $1.28B | $1.24B | -34.3% |
| Property, plant & equipment | $13.40M | $16.00M | $14.00M | $17.80M | -16.3% |
| Total assets | $717.90M | $1.09B | $1.30B | $1.27B | -34.2% |
| Total current liabilities | $142.50M | $229.80M | $257.10M | $295.10M | -38.0% |
| Long-term debt | $400.00K | $600.00K | $800.00K | $1.00M | -33.3% |
| Total debt | $8.90M | $9.70M | $3.20M | $5.50M | -8.2% |
| Total liabilities | $284.10M | $529.80M | $644.60M | $703.90M | -46.4% |
| Retained earnings | -$1.61B | -$1.53B | -$1.33B | -$965.40M | -5.3% |
| Shareholder equity | $433.80M | $561.60M | $660.00M | $564.90M | -22.8% |
| Working capital | $558.20M | $837.50M | $1.02B | $945.10M | -33.3% |
| Net tangible assets | $433.80M | $561.60M | $660.00M | $564.90M | -22.8% |
| Shares issued | 73.50M | 68.80M | 68.00M | 53.20M | +6.8% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$80.80M | -$198.90M | -$367.30M | -$282.50M | +59.4% |
| Depreciation & amortisation | $5.20M | $6.60M | $6.70M | $8.20M | -21.2% |
| Stock-based compensation | $44.00M | $88.20M | $71.60M | $75.50M | -50.1% |
| Change in working capital | -$233.70M | -$140.60M | -$44.40M | -$82.60M | -66.2% |
| Operating cash flow | -$273.80M | -$259.30M | -$347.80M | -$273.50M | -5.6% |
| Capital expenditure | -$1.90M | -$1.80M | -$2.90M | -$6.80M | -5.6% |
| Investing cash flow | $407.60M | $34.70M | $203.50M | $242.80M | +1,074.6% |
| Share buybacks | -$91.90M | $0 | $0 | — | — |
| Financing cash flow | -$91.40M | $7.90M | $374.70M | $4.70M | -1,257.0% |
| Free cash flow | -$275.70M | -$261.10M | -$350.70M | -$280.30M | -5.6% |
| End cash position | $142.90M | $100.50M | $317.20M | $86.80M | +42.2% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $249.70M | $15.60M | $9.50M | $41.90M | $22.40M | +1,500.6% |
| Operating revenue | $249.70M | $15.60M | $9.50M | $41.90M | $22.40M | +1,500.6% |
| Research & development | $52.60M | $60.30M | $61.10M | $64.70M | $68.60M | -12.8% |
| Selling, general & admin | $24.00M | $19.10M | $23.00M | $21.00M | $25.30M | +25.7% |
| Total operating expense | $85.60M | $79.40M | $84.10M | $85.70M | $93.90M | +7.8% |
| Operating income | $164.10M | -$63.80M | -$74.60M | -$43.80M | -$71.50M | +357.2% |
| Net interest income | $5.50M | $6.40M | $7.40M | $9.00M | $10.30M | -14.1% |
| Pre-tax income | $169.60M | -$57.50M | -$67.20M | -$34.80M | -$61.50M | +395.0% |
| Tax provision | $200.00K | $100.00K | $200.00K | $300.00K | -$300.00K | +100.0% |
| Net income | $169.40M | -$57.60M | -$67.40M | -$35.10M | -$61.20M | +394.1% |
| Net income to common | $169.40M | -$57.60M | -$67.40M | -$35.10M | -$61.20M | +394.1% |
| Basic EPS | 2.61 | -0.90 | -1.10 | -0.48 | -0.84 | +390.0% |
| Diluted EPS | 2.58 | -0.90 | -1.10 | -0.48 | -0.84 | +386.7% |
| EBIT | $164.10M | -$63.80M | -$74.60M | -$43.80M | -$71.50M | +357.2% |
| EBITDA | $165.30M | -$62.70M | -$73.40M | -$42.50M | -$70.10M | +363.6% |
| Basic shares | 64.80M | 64.00M | 64.90M | 73.20M | 73.00M | +1.3% |
| Diluted shares | 65.70M | 64.00M | 64.90M | 73.20M | 73.00M | +2.7% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $94.30M | $87.30M | $142.90M | $101.50M | $114.90M | +8.0% |
| Cash & short-term investments | $567.90M | $614.90M | $685.40M | $787.60M | $861.20M | -7.6% |
| Accounts receivable | $50.30M | $1.80M | $1.00M | $20.30M | $500.00K | +2,694.4% |
| Total current assets | $652.20M | $630.70M | $700.70M | $826.30M | $889.50M | +3.4% |
| Property, plant & equipment | $12.30M | $13.30M | $13.40M | $14.10M | $15.40M | -7.5% |
| Total assets | $675.10M | $647.50M | $717.90M | $844.30M | $909.30M | +4.3% |
| Total current liabilities | $82.50M | $115.90M | $142.50M | $144.90M | $157.80M | -28.8% |
| Long-term debt | $300.00K | $300.00K | $400.00K | $400.00K | $500.00K | 0.0% |
| Total debt | $8.00M | $8.40M | $8.90M | $9.30M | $9.90M | -4.8% |
| Total liabilities | $113.00M | $260.70M | $284.10M | $279.90M | $300.00M | -56.7% |
| Retained earnings | -$1.50B | -$1.67B | -$1.61B | -$1.54B | -$1.51B | +10.1% |
| Shareholder equity | $562.10M | $386.80M | $433.80M | $564.40M | $609.30M | +45.3% |
| Working capital | $569.70M | $514.80M | $558.20M | $681.40M | $731.70M | +10.7% |
| Net tangible assets | $562.10M | $386.80M | $433.80M | $564.40M | $609.30M | +45.3% |
| Shares issued | 65.30M | 74.51M | 73.50M | 73.42M | 73.20M | -12.4% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | $169.40M | -$57.60M | -$67.40M | -$35.10M | -$61.20M | +394.1% |
| Depreciation & amortisation | $1.20M | $1.10M | $1.20M | $1.30M | $1.40M | +9.1% |
| Stock-based compensation | $5.90M | $12.10M | $8.50M | $10.20M | $10.30M | -51.2% |
| Change in working capital | -$226.50M | -$23.40M | $29.50M | -$32.80M | -$42.80M | -867.9% |
| Operating cash flow | -$48.30M | -$69.20M | -$30.40M | -$59.10M | -$95.40M | +30.2% |
| Capital expenditure | -$200.00K | -$1.30M | -$200.00K | -$100.00K | -$1.20M | +84.6% |
| Investing cash flow | $54.90M | $13.70M | $145.80M | $63.50M | $128.80M | +300.7% |
| Share buybacks | — | — | -$74.10M | — | — | — |
| Financing cash flow | $400.00K | -$100.00K | -$74.00M | -$17.80M | $500.00K | +500.0% |
| Free cash flow | -$48.50M | -$70.50M | -$30.60M | -$59.20M | -$96.60M | +31.2% |
| End cash position | $94.30M | $87.30M | $142.90M | $101.50M | $114.90M | +8.0% |
Options analytics
Put / call volume
0.09
Call-heavy session
Put / call open interest
0.01
Positioning, not flow
Max pain
7.00
-4.2% from spot
ATM implied vol
407.8%
Nearest strike to spot
Skew (10% OTM)
0.0%
Calls bid over puts
Call volume
280
Contracts, this expiry
Put volume
25
Contracts, this expiry
Heaviest call OI
15.00
64 contracts
Heaviest put OI
11.00
1 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.28 | 2.58 | +1,012.4% |
| Mar 2026 | -0.96 | -0.90 | +6.7% |
| Dec 2025 | -0.57 | -1.10 | -94.3% |
| Sep 2025 | -0.74 | -0.48 | +35.5% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.95 | 12 | $16.82M | -59.9% |
| Next quarter | -0.93 | 12 | $15.51M | +63.3% |
| Current year | -0.14 | 12 | $296.10M | +12.8% |
| Next year | -3.23 | 12 | $64.19M | -78.3% |
Analyst targets & ownership
Mean target$13.93
High target$21.00
Low target$6.00
Implied upside91.08%
Analyst count14
ConsensusBUY
Strong buy / Buy2 / 5
Hold8
Sell / Strong sell1 / 0
Held by insiders7.80%
Held by institutions83.94%
Institutions holding284
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
7.56
-3.54% from price
SMA 20
7.99
-8.46% from price
SMA 50
8.59
-14.85% from price
SMA 100
8.39
-13.10% from price
SMA 200
10.09
-27.58% from price
EMA 12
7.69
-5.24% from price
EMA 26
8.08
-9.75% from price
EMA 50
8.35
-12.74% from price
RSI (14)
31.2
Neutral
MACD (12,26,9)
-0.38
Hist -0.06
ATR (14)
0.33
4.47% of price
Realised vol 30D
38.4%
Annualised
Bollinger upper
8.91
20, 2σ
Bollinger lower
7.06
20, 2σ
50 / 200 cross
Death
8.59 vs 10.09
Trend bias
Below 200
-27.58%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
1.16
More volatile than market
Correlation to SPY
0.28
Largely independent
Realised vol 30D
38.4%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-49.5%
Peak to trough
Max drawdown 5Y
-93.7%
Peak to trough
ATR 14
0.33
4.47% of price
Beta (reported)
1.81
5Y monthly, from filing
Short interest
Shares short
4.99M
Prior 4.05M
Change vs prior
+23.1%
Shorts adding
% of float
8.89%
Normal
% of shares out
7.63%
Against total outstanding
Days to cover
6.8
Crowded exit
Float
56.81M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 10, 26 | Evercore ISI Group | MAINTAINED | Outperform | Outperform |
| Aug 10, 26 | Citigroup | MAINTAINED | Buy | Buy |
| Aug 5, 26 | Wells Fargo | DOWNGRADE | Overweight | Equal-Weight |
| Aug 5, 26 | Wedbush | MAINTAINED | Neutral | Neutral |
| Aug 4, 26 | BTIG | MAINTAINED | Buy | Buy |
| Jun 3, 26 | Stephens & Co. | MAINTAINED | Overweight | Overweight |
| May 13, 26 | Barclays | MAINTAINED | Overweight | Overweight |
| May 13, 26 | BTIG | MAINTAINED | Buy | Buy |
| May 4, 26 | Citigroup | MAINTAINED | Buy | Buy |
| Mar 19, 26 | Citigroup | MAINTAINED | Buy | Buy |
| Mar 19, 26 | BTIG | MAINTAINED | Buy | Buy |
| Mar 5, 26 | Citigroup | MAINTAINED | Buy | Buy |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay date—
Last split—
Split date—
SEC filings
Offering Registrations
S-8 · 2026-09-28
Offering Registrations
S-8 · 2026-08-31
Periodic Financial Reports
10-Q · 2026-08-04
Corporate Changes & Voting Matters
8-K · 2026-06-25
Corporate Changes & Voting Matters
8-K · 2026-06-22
Corporate Changes & Voting Matters
8-K · 2026-06-16
Corporate Changes & Voting Matters
8-K · 2026-06-02
Corporate Changes & Voting Matters
8-K · 2026-05-12
Headlines
Arvinas to Present Novel Biomarker Data from the Phase 1 Clinical Trial for ARV-102, a PROTAC LRRK2 Degrader, at the 2026 International Congress of Parkinson’s Disease and Movement Disorders®
GlobeNewswire · 5d ago
Arvinas Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire · 7d ago
Arvinas Announces First Patient Dosed in Phase 1/2 Clinical Trial of ARV-6723, the Company’s First Immuno-Oncology Candidate
GlobeNewswire · 9d ago
Ginkgo Bioworks (DNA) Surges 11.1%: Is This an Indication of Further Gains?
Zacks · 19d ago
AdvanCell Appoints Sean Cassidy as Chief Financial Officer
Business Wire · 22d ago
Arvinas (ARVN) Just Made Protein Degrader History With FDA Nod
Insider Monkey · 28d ago
Arvinas to Participate in Upcoming Investor Conferences
GlobeNewswire · 33d ago
Can KT-621 Mark a Turning Point for Kymera Therapeutics?
Zacks · 34d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.